Short answer
Protagonist Therapeutics, Inc (PTGX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $5M (up 0.8% year over year) with net income of −$39M.
Q3 2025 key financials · XBRL
- Revenue
- $5M
- +0.8% YoY · −15.0% QoQ
- Net income
- −$39M
- −18.5% YoY · −13.1% QoQ
- Operating margin
- -985.2%
- EPS (diluted)
- −$0.62
- −12.7% YoY · −14.8% QoQ
Source: XBRL data from the Protagonist Therapeutics, Inc (PTGX) Q3 2025 10-Q on SEC EDGAR. USD.
Protagonist Therapeutics, Inc Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New FDA disruption risk triggered by mass federal employee layoffs since January 2025 and ongoing government shutdown starting October 2025
- Updated macroeconomic risk from U.S. tariffs up to 100% on imported branded pharmaceuticals announced September 2025 with unclear implementation timing
- Regulatory risk intensifies due to legal challenges and uncertainty around FDA funding, leadership, and policy changes under current presidential administration
- Market risk from geopolitical conflicts (Russia-Ukraine, Middle East, China-Taiwan tensions) causing commodity price volatility and supply chain disruptions
- Financial risk from volatile credit markets and potential difficulty securing financing, risking delays or abandonment of clinical development plans
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protagonist Therapeutics, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.